News stories about ImmuCell Corporation (NASDAQ:ICCC) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ImmuCell Corporation earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.5744474282646 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

ImmuCell Corporation (NASDAQ ICCC) traded down 0.13% on Tuesday, hitting $7.40. The stock had a trading volume of 4,576 shares. The company has a 50-day moving average price of $6.84 and a 200-day moving average price of $6.01. ImmuCell Corporation has a 52 week low of $4.76 and a 52 week high of $8.24. The stock has a market capitalization of $35.88 million, a price-to-earnings ratio of 51.75 and a beta of 1.02.

ImmuCell Corporation (NASDAQ:ICCC) last released its quarterly earnings results on Thursday, May 11th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter. The business had revenue of $3.54 million during the quarter. ImmuCell Corporation had a return on equity of 3.52% and a net margin of 6.34%.

Separately, TheStreet raised ImmuCell Corporation from a “c” rating to a “b-” rating in a research report on Monday, June 12th.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact ImmuCell Corporation (ICCC) Share Price” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at

In related news, insider Brian L. Pessin purchased 30,000 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of $5.25 per share, for a total transaction of $157,500.00. Following the purchase, the insider now owns 70,000 shares of the company’s stock, valued at $367,500. The transaction was disclosed in a filing with the SEC, which is available at this link. 20.10% of the stock is currently owned by insiders.

About ImmuCell Corporation

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Insider Buying and Selling by Quarter for ImmuCell Corporation (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related companies with's FREE daily email newsletter.